Collaboration aims to bolster high-quality services for early-phase development.
Biopharmaceutical services provider Parexel International signed an agreement with the Asan Medical Center (AMC) in Soeul, Korea, to provide global clients with access to clinical trial services throughout Asia, with a particular focus on early phase development. AMC is a medical complex and large, clinical-research centered hospital, which is supported by the AMC Clinical Trial Center and department of clinical pharmacology and therapeutics. Opened in 2002, the AMC Clinical Trial Center was designated as the Regional Clinical Trial Center by the Korean Ministry for Health, Welfare, and Family Affairs in 2006.
“Parexel provides clients with patient access in key therapeutic areas for early-phase development through our early-phase units and global alliance network,” explains Mark A. Goldberg, M.D. “Our relationship with the Asan Medical Center affords us the opportunity to further extend this capability into Asia. With Asan Medical Center’s leadership in clinical trials, in-depth expertise, state-of-the art facilities, and a renowned network of hospitals, we believe our alliance will offer unique advantages to the Korean biopharmaceutical industry.”
Parexel offers a broad range of clinical development capabilities and services, technologies, regulatory affairs consulting, and commercialization services. The firm has had a presence in the Asia/Pacific region for over 16 years, which currently includes more than 2,800 employees and 21 offices in major industry centers in the region, including Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, the Philippines, Singapore, South Korea, Taiwan, and Thailand.